Probiotic Therapy in Early Pregnancy May Significantly Lower Recurrent Premature Birth Risk

University of Toyama researchers discover that Clostridium butyricum probiotics taken early in pregnancy significantly lower the risk of recurrent premature birth.

By: AXL Media

Published: Mar 30, 2026, 10:35 AM EDT

Source: Information for this report was sourced from the University of Toyama

The Immune-Pregnancy Axis and Preterm Birth

Preterm birth remains a primary global challenge in obstetric medicine, frequently leading to respiratory distress, neurological injury, and long-term developmental disabilities in newborns. For women with a history of spontaneous preterm delivery (sPTD), the risk of recurrence in subsequent pregnancies is a persistent concern. Research led by Associate Professor Satoshi Yoneda at the University of Toyama suggests that the key to prevention may lie in the maternal–fetal immune interface. A successful pregnancy requires regulatory T cells (Treg cells) to maintain a delicate balance, suppressing inflammation while tolerating the developing fetus—a process influenced heavily by the gut microbiome.

Restoring Beneficial Gut Bacteria with Clostridium butyricum

The study focused on Clostridium butyricum, a butyrate-producing bacterium known to promote the development of protective Treg cells. Previous clinical observations had noted a marked deficiency of these bacteria in women who experienced sPTD. To test whether restoring these levels could stabilize the immune environment, researchers enrolled 315 pregnant women across 31 Japanese hospitals who had previously experienced a premature delivery. Starting between 10 and 14 weeks of gestation, these participants received daily oral probiotic tablets containing C. butyricum, Enterococcus faecium, and Bacillus subtilis.

Statistical Reduction in Recurrent Delivery Rates

The results of the prospective trial indicate a significant shift in clinical outcomes for high-risk pregnancies. While the national perinatal database in Japan reports a 22.3% recurrence rate for sPTD, the group receiving probiotic therapy saw that figure drop to 14.9%. The intervention also appeared effective in reducing the most severe cases of extremely preterm births. Importantly, the probiotic regimen demonstrated a favorable safety profile, with no serious adverse events reported, making it a potentially low-risk addition to standard prenatal care protocols.